Harvard dominates high-quality cancer research publishing, having widened the gap between itself and the Chinese Academy of Sciences dramically over the past few years.
go.nature.com/3EoPuQi
go.nature.com/3EoPuQi
May 7, 2025 at 4:55 AM
Harvard dominates high-quality cancer research publishing, having widened the gap between itself and the Chinese Academy of Sciences dramically over the past few years.
go.nature.com/3EoPuQi
go.nature.com/3EoPuQi
The US is responsible for more than half of the global public and philanthropic funding for cancer research. Funding cuts, like we've seen recently under Trump, pose a serious risk to new tests and treatments:
go.nature.com/3EoPuQi
go.nature.com/3EoPuQi
May 6, 2025 at 3:48 AM
The US is responsible for more than half of the global public and philanthropic funding for cancer research. Funding cuts, like we've seen recently under Trump, pose a serious risk to new tests and treatments:
go.nature.com/3EoPuQi
go.nature.com/3EoPuQi
Chinese companies have overtaken the US in cancer clinical trial starts. Its rise to the top is unlike anything we've seen from other leading science nations: go.nature.com/3EoPuQi
May 6, 2025 at 3:33 AM
Chinese companies have overtaken the US in cancer clinical trial starts. Its rise to the top is unlike anything we've seen from other leading science nations: go.nature.com/3EoPuQi